This study examines the effect of the introduction of new laboratory procedures and other medical goods and services on the health of Americans during the period 1990-2003. We hypothesize that, the more medical innovation there is related to a medical condition, the greater the improvement in the average health of people with that condition. To test this hypothesis, we estimate models of health outcomes using longitudinal disease-level data. We measure innovation in five types of medical procedures or products: pathology & laboratory procedures, outpatient prescription drugs, inpatient prescription drugs, surgical procedures, and diagnostic radiology procedures.
Economists believe that the development of new products is the main reason why people are better off today than they were several generations ago. In their 1993 book, Innovation and Growth in the Global Economy, Grossman and Helpman argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." In their 1996 book, The Economics of New Goods, Bresnahan and Gordon stated simply that "new goods are at the heart of economic progress." And in a recent paper, Measuring the Growth from Better and Better Goods, Bils (2004) makes the case that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models." New goods do not emerge ex nihilo. They are usually the result of investment in research and development (R&D) . National Science Foundation data reveal that the medical equipment and supplies industry is one of the most research-intensive industries in the economy. As Figure 1 indicates, the ratio of R&D expenditure to sales is two and a half times as high in this industry as it is in the average American industry.
In this paper I will examine the impact of a subset of the new products generated by this industry-clinical laboratory products-on the longevity and quality of life of Americans. FDA data indicate that, in the last decade, about 100 of these new products have been introduced. I hypothesize that these new products have improved the quality of information physicians and patients have about patients' medical conditions, and have therefore enabled more appropriate and effective treatment of those conditions. This may be illustrated by two new kinds of tests: HIV tests, and genetic tests related to dosing of a widely prescribed anti-blood clotting drug.
For almost two decades, HIV tests had two glaring flaws. They did not detect the earliest stage of infection, when people are more likely to spread the virus. They also took days to produce results, and many people never returned to learn whether they were infected. New generations of tests can largely eliminate either the long waiting time for results, or the failure to find early infections (but not both) (New York Times (2005a) ).
About two million Americans take warfarin (Coumadin) each day to help prevent blood clots because of problems like a heart attack, an abnormal heart rhythm, a stroke or major surgery. Establishing a proper dose of warfarin as patients start taking the drug is one of the peskiest problems in medical practice. Misjudgments in doses can critically affect the clotting mechanism, leading to potentially fatal bleeding. At present, doctors rely on costly blood tests that must be repeated frequently over a period of months to adjust the dose to ensure that the drug will work safely. But a recent study suggests that it may be possible to develop a standard genetic test that would allow doctors to quickly and precisely choose a safe starting dose of warfarin (New York Times (2005b) ). This study will examine the effect of the introduction of new laboratory procedures and other medical goods and services on the health of Americans during the period 1990-2003.
Econometric specification
We hypothesize that, the more medical innovation there is related to a medical condition, the greater the improvement in the average health of people with that condition. To test this hypothesis, we will estimate the following model, using longitudinal disease-level data:
where H_END i = a measure of the average health of people with medical condition i at the end of a period H_BEGIN i = a measure of the average health of people with medical condition i at the beginning of the period INNOV ji = a measure of innovation of type j in the treatment of condition i during the period Z i = other attributes of medical condition i
We will measure innovation in five types of medical procedures or products (j = 1,…,5):
pathology & laboratory procedures (henceforth referred to as lab procedures), outpatient prescription drugs, drugs administered by providers (e.g. chemotherapy; henceforth referred to as inpatient prescription drugs), surgical procedures, and diagnostic radiology procedures.
We will examine two kinds of (inverse) indicators of health: mortality and disability. The mortality indicator we will analyze is the mean age at death of people whose underlying cause of death is medical condition i. Data on mean age at death (and the number of deaths), by cause, were obtained from the Multiple Cause-of-Death The disability measures we will analyze are the fraction of people with medical condition i who (1) missed work, or (2) spent one or more days in bed, due to that condition. These data were constructed from the Medical Conditions files of the 1996 and 2003 waves of the Medical Expenditure Panel Survey (MEPS).
Eq. (1) will be estimated via weighted least-squares, where the weight is equal to the mean number of observations from which the dependent variable was computed ((N_BEGIN i + N_END i )/2). In the mortality analysis, the weight is the mean of the number of 1990 and 1998 deaths due to underlying cause i. In the disability analysis, the weight is the mean of the number of records in the 1996 and 2003 Medical Conditions files associated with condition i. The data are consistent with the hypothesis that the variance of (H_END i -H_BEGIN i ) is inversely proportional to ((N_BEGIN i + N_END i )/2). Figure 1 depicts the relationship across conditions between the 1990-1998 change in the mean age at death and the mean number of deaths. The variance of the change in the mean age at death is much lower for conditions causing a larger number of deaths.
Measures of innovation in the treatment of a condition during a period were constructed as follows:
where FREQ pji = the number of times procedure p of type j was performed on patients with diagnosis i in the last year of a period NEW p = 1 if the CPT code for procedure p was established by the AMA after the beginning of the period = 0 otherwise Data on utilization of medical procedures and products, by diagnosis (FREQ pji ), were obtained from the MEDSTAT Marketscan database. MEDSTAT contains data on outpatient and inpatient services (procedures) and outpatient prescriptions of hundreds of thousands, or even millions, of individuals. Each outpatient and inpatient service record contains one procedure code (usually a CPT code), one or more ICD-9 diagnosis codes, and the amount paid for the procedure. Hence, we can compute the frequency of procedures performed (and expenditure), by CPT code and ICD-9 code, in each year (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) .
The year in which CPT codes for laboratory, surgery, and radiology procedures were first established by the American Medical Association was determined from the AMA's publication CPT Assistant Archives 1990 -2003 determine the year in which each active ingredient was first approved by the FDA.
MEDSTAT outpatient prescription drug claims do not include diagnosis codes, so we used a different source of data on outpatient prescription drugs that links prescriptions written with diagnoses: the National Ambulatory Medical Care Survey (NAMCS).
Sample characteristics
We have data on utilization of medical procedures and products during the period 1990-2003. However, the sample period for the mortality analysis is restricted to 1990-1998, and the sample period for the disability analysis is restricted to 1996-2003.
The initial year for the mortality analysis is 1990 because the data on the dates at which CPT codes were established are left-censored: if a CPT code was established before 1990, we can't determine the year in which it was established. The final year is 1998 because the disease classification system used to code underlying cause-of-death for deaths that occurred after 1998 is different from that used to code underlying cause-ofdeath for deaths that occurred earlier and from that used to code patient diagnoses in MEDSTAT, NAMCS, and MEPS. The disease classification system used to code underlying cause-of-death for deaths that occurred in the United States during 1979-98, and to code patient diagnoses in MEDSTAT, NAMCS, and MEPS data, is the Ninth Revision of the International Classification of Diseases (ICD-9). The Tenth Revision of the ICD (ICD-10) was used to 1 Level II of the HCPCS is a standardized coding system that is used primarily to identify products, supplies, and services not included in the CPT codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office. Because Medicare and other insurers cover a variety of services, supplies, and equipment that are not identified by CPT codes, the level II HCPCS codes were established for submitting claims for these items. The development and use of level II of the HCPCS began in the 1980's. Level II codes are also referred to as alpha-numeric codes because they consist of a single alphabetical letter followed by 4 numeric digits, while CPT codes are identified using 5 numeric digits. See http://www.cms.hhs.gov/medicare/hcpcs/codpayproc.asp code underlying cause-of-death for deaths that occurred in 1999 and later years. The ICD-9 and ICD-10 classification systems are quite different. The ICD-9 system has a 4digit numeric structure and about 5,000 categories for classifying cause-of-death. The ICD-10 system has a 4-digit alphanumeric coding structure and about 8,000 categories for classifying cause-of-death. Comparison of ICD-9 and ICD-10 shows that new chapters have been added to the ICD, old chapters have been rearranged, causes of death have been regrouped, and titles have changed. As a result of these changes, the two classification schemes are different enough to make direct comparisons of cause-of-death
The sample period for the disability analysis is restricted to 1996-2003, because 1996 was the first year in which the MEPS was conducted.
We will analyze data at the 3-digit ICD-9 level. 3 We exclude medical conditions due to injury and poisoning (ICD-9 codes 800-999). The models we estimate will be based on data on about 400 diseases. About 1100 distinct lab tests (CPT codes) appear in the 1998 MEDSTAT data. Table 2 lists the 20 lab procedures performed in 1998 with the highest total cost. Table 3 lists the 20 post-1990 lab procedures performed in 1998 with the highest total cost. Table 4 shows summary mortality and innovation statistics for the sample of 3digit ICD-9 diseases during the period 1990-1998. Table 5 shows mortality and laboratory innovation data for the 30 largest causes of death. Note that the extent of laboratory innovation varied considerably across diseases. For some diseases, less than 16% of lab procedures were post-1990 procedures. In contrast, 33% of the lab procedures for prostate cancer, and 41% of the lab procedures for HIV, were post-1990
Descriptive statistics
procedures.
Mortality results
Estimates of models of the 1990-1998 change in mean age at death are presented in Table 6 . We estimated four different models. All models include five innovation measures (lab procedures, outpatient rx, inpatient rx, surgical procedures, and diagnostic radiology procedures), and the 1990-1998 change in the log of the number of deaths.
HIV is included in models 1 and 2, but excluded from models 3 and 4. As shown in Table 5 , among high-mortality diseases HIV is an outlier in terms of both laboratory innovation and increase in mean age at death. It is therefore of interest to assess the sensitivity of the estimates to the inclusion of this observation.
Eq.
(1) may be viewed as a special case of the following equation, in which the restriction π = 1 is imposed:
Inclusion of H_BEGIN in eq. (4) is referred to as "baseline adjustment". Arguments can be made both for and against baseline adjustment. The argument for is that mean age at death may be subject to regression to the mean: diseases with high initial mean ages at death are likely to experience smaller increases in mean age at death (π < 1). If this is true, and innovation is correlated with initial mean age at death, imposing the restriction π = 1 may result in biased estimates of the β's. In particular, if innovation is inversely related to initial mean age at death-there is more innovation for diseases with the worst initial health-then the β's may be overestimated.
In our sample, there is a significant inverse relationship between initial health (e.g. mean age at death) and the extent of laboratory and inpatient rx innovation: the rates of innovation (% of new procedures) are highest for diseases with the worst initial health.
Initial health is uncorrelated with the rates of outpatient rx and diagnostic radiology innovation, and positively correlated with surgical innovation: there was more surgical innovation for diseases with high initial mean ages at death.
If H_BEGIN were measured without error, estimates of β j 's from the unrestricted model (4) would be more reliable than estimates from the restricted model (1). In practice, however, H_BEGIN is measured with error. In the presence of measurement error, the estimate of π is biased towards zero: the estimate of π will be significantly less than 1 even when true π = 1. Moreover, the bias will be transmitted to estimates of coefficients on other regressors that are correlated with H_BEGIN. In particular, coefficients on other regressors that are negatively correlated with H_BEGIN will also be biased towards zero.
Previous investigators have recognized the potential pitfalls of baseline adjustment. Campbell and Kenny (2002) argued there "are instances when problems are actually created, instead of solved, by 'correction' for regression toward the mean." And Glymour et al (2005) Models 1 and 3 do not control for initial health (mean age at death in 1990); models 2 and 4 do. The true effect of innovation on health may be bounded between estimates from models that don't and do control for initial health.
Consider the estimates of Model 1 in Table 6 . The coefficients on laboratory, outpatient rx, and inpatient rx innovation are positive and highly significant: diseases with above-average rates of these types of innovation had above-average increases in mean age at death. The coefficient on diagnostic radiology innovation is only marginally significant (p-value = .16), and the coefficient on surgical innovation is not significant. 4
The positive coefficient on the 1990-1998 change in the log of the number of deaths indicates that diseases with larger percentage increases in the number of deaths tended to have larger increases in mean age at death.
Model 2 controls for initial mean age at death, and (like Model 1) is based on a sample including HIV. Not surprisingly, the coefficient on initial health is negative and highly significant: mean age at death increased more for diseases with low initial ages.
Controlling for initial health has little effect on the outpatient rx coefficient. However, it reduces the magnitude of the lab innovation coefficient by about 50%, and the coefficient on inpatient rx innovation is no longer significant. The lab innovation coefficient is now significant at the 6% level. To summarize the estimates, in all four models, the coefficients on lab innovation and outpatient rx innovation are positive and significant at at least the 6% level; in some models these coefficients are much more significant. Controlling for initial health reduces the magnitude and significance of the lab and (especially) the inpatient rx 4 Measuring surgical innovation using CPT code changes may be problematic. Closer inspection of the data on surgical procedures reveals that some "new" procedures are probably just relabeled or reclassified old procedures, rather than true innovations. For example, the three procedures whose codes were added in 1997 which were most frequently performed in 1997 were 98940, 98941, and 98942, which correspond to different types of chiropractic manipulative treatment of the spine. Undoubtedly, this type of treatment was performed well before 1997. A new CPT code should therefore be considered a necessary condition for a medical innovation, but not a sufficient condition: all innovations have new CPT codes, but some new CPT codes are not innovations. The fraction of procedures with new CPT codes exceeds the fraction of truly innovative procedures, perhaps by a significant amount, and the degree of overstatement varies across diseases. In the future, I hope to develop a reliable method of distinguishing between truly innovative procedures and old procedures with new CPT codes.
innovation coefficients, but if poor initial health stimulates innovation, controlling for initial health may bias these coefficients downward. Now we will assess the implications of the estimates of Model 2, which has the lowest lab innovation coefficient and the second lowest outpatient rx coefficient. As shown in Table 4 , 20% of the lab procedures performed in 1998 were post-1990
procedures. The 1990 Table 7 shows In Model 2, the dependent variable is the 1996-2003 change in the fraction of people who had any bed days, and we again don't control for the level of disability in 1996. The lab innovation coefficient is somewhat smaller, and is significant at the 7% level. This suggests that conditions with higher rates of lab innovation during [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] had greater declines in the probability of having bed days.
Disability results
Models 3 and 4 control for the level of disability in 1996. When we control for initial disability, the lab and drug innovation coefficients are all statistically insignificant.
In this sample, as in the mortality sample, there is a significant inverse relationship between initial health and the extent of laboratory innovation: the % of new lab procedures is higher for diseases with the highest initial rates of missed work and bed days. Due to errors in measuring initial health, controlling for this variable may cause the impact of innovation on health to be underestimated.
Summary
This study has examined the effect of the introduction of new laboratory procedures and other medical goods and services on the health of Americans during the period 1990-2003. We hypothesized that, the more medical innovation there is related to a medical condition, the greater the improvement in the average health of people with that condition. To test this hypothesis, we estimated models of health outcomes using longitudinal disease-level data. We measured innovation in five types of medical procedures or products: pathology & laboratory procedures, outpatient prescription drugs, inpatient prescription drugs, surgical procedures, and diagnostic radiology procedures.
We examined two kinds of (inverse) indicators of health: mortality and disability.
The mortality indicator we analyzed is the mean age at death of people whose underlying cause of death is medical condition i. The disability measures we analyzed are the fraction of people with medical condition i who (1) missed work, or (2) spent one or more days in bed, due to that condition.
Our estimates indicated that conditions with higher rates of lab and outpatient drug innovation had larger increases in mean age at death, controlling for other medical innovation rates and initial mean age at death. The 1990-1998 increase in mean age at death attributable to use of new lab procedures is estimated to be about 6 months. This is 42% of the total increase in mean age at death (1.18 years) in our sample of diseases.
New laboratory procedures introduced during 1990-1998 are estimated to have saved 1.13 million life-years in 1998. Expenditure per life-year gained from new lab procedures is estimated to be $6093. Treatments that cost this amount are generally considered to be quite cost-effective.
In the analysis of disability, when we didn't control for the initial level of disability, we found that conditions with higher rates of lab and outpatient innovation had greater declines in the probability of missing work during 1996-2003. This suggested that the use of new laboratory procedures reduced the number of work-loss days in 2003 by 42 million. When we controlled for initial disability, the inverse relationship between lab innovation and disability changes disappeared. This is because there is a significant inverse relationship between initial health and the extent of laboratory innovation. Due to errors in measuring initial health, controlling for this variable may cause the impact of innovation on health to be underestimated. 10 100 1,000 10,000 100,000 1,000,000
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